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Objectives This study evaluated the efficacy and safety of flecainide in addition to conventional drug therapy in patients
with catecholaminergic polymorphic ventricular tachycardia (CPVT).
Background CPVT is an inherited arrhythmia syndrome caused by gene mutations that destabilize cardiac ryanodine receptor
Ca2 release channels. Sudden cardiac death is incompletely prevented by conventional drug therapy with
-blockers with or without Ca2 channel blockers. The antiarrhythmic agent flecainide directly targets the molec-
ular defect in CPVT by inhibiting premature Ca2 release and triggered beats in vitro.
Methods We collected data from every consecutive genotype-positive CPVT patient started on flecainide at 8 international
centers before December 2009. The primary outcome measure was the reduction of ventricular arrhythmias
during exercise testing.
Results Thirty-three patients received flecainide because of exercise-induced ventricular arrhythmias despite conven-
tional (for different reasons, not always optimal) therapy (median age 25 years; range 7 to 68 years; 73% fe-
male). Exercise tests comparing flecainide in addition to conventional therapy with conventional therapy alone
were available for 29 patients. Twenty-two patients (76%) had either partial (n  8) or complete (n  14) sup-
pression of exercise-induced ventricular arrhythmias with flecainide (p  0.001). No patient experienced worsen-
ing of exercise-induced ventricular arrhythmias. The median daily flecainide dose in responders was 150 mg
(range 100 to 300 mg). During a median follow-up of 20 months (range 12 to 40 months), 1 patient experi-
enced implantable cardioverter-defibrillator shocks for polymorphic ventricular arrhythmias, which were associ-
ated with a low serum flecainide level. In 1 patient, flecainide successfully suppressed exercise-induced ventricu-
lar arrhythmias for 29 years.
Conclusions Flecainide reduced exercise-induced ventricular arrhythmias in patients with CPVT not controlled by conventional drug
therapy. (J Am Coll Cardiol 2011;57:2244–54) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.026Catecholaminergic polymorphic ventricular tachycardia
(CPVT) is a malignant inherited arrhythmia syndrome char-
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May 31, 2011:2244–54 Flecainide Therapy in CPVTnormal hearts, with a high fatal event rate in untreated
patients (1–3). Approximately 60% of CPVT patients have
mutations in genes encoding the cardiac ryanodine receptor
Ca2 release channel (RyR2) or cardiac calsequestrin (4–6),
and these cause spontaneous RyR2 channel openings (7,8).
The resulting increase in cytosolic Ca2 triggers delayed
fterdepolarizations, ventricular premature beats (VPBs),
nd ventricular tachycardia, especially under conditions of
-adrenergic stimulation (9,10).
Hence, -blockers are considered first-line therapy, but
unfortunately they are not completely effective in preventing
life-threatening arrhythmias (1–3,11–16). An implantable
cardioverter-defibrillator (ICD) is often used in patients
who continue to have ventricular arrhythmias despite
-blocker therapy. However, ICDs are not fully protective
and can be proarrhythmic in CPVT patients because both
appropriate and inappropriate ICD shocks can trigger
catecholamine release, subsequently resulting in multiple
shocks (arrhythmic storm), and death (17,18). Thus, addi-
tional therapy is desired for CPVT. Small case series show
that left cardiac sympathetic denervation is effective in
patients who are insufficiently protected by -blocker ther-
py and/or experiencing too many ICD shocks (19–22).
Recently, we discovered that the antiarrhythmic agent
ecainide directly blocks RyR2 channels, prevents RyR2-
ediated premature Ca2 release, and suppresses triggered
eats in myocytes isolated from mouse hearts lacking
alsequestrin, an animal model of CPVT (23). This effect is
ot mediated by Na-channel block, the conventional mode
of action thought to underlie flecainide activity, but rather
can be attributed to open state block of RyR2 channels (that
is, flecainide directly targets the molecular defect responsible
for the arrhythmogenic Ca2 waves that trigger CPVT in
vivo) (24). In preliminary work, flecainide also appeared to
be effective in 2 highly symptomatic CPVT patients (23).
Here we collate the data from every CPVT patient started
on flecainide at 8 international centers and report on the
efficacy and safety of flecainide treatment in CPVT.
Methods
Participants and study design. To better understand the
efficacy and safety of flecainide in CPVT, we reviewed the
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patient in whom flecainide was
started at 8 tertiary referral cen-
ters in the Netherlands, Canada,
France, Israel, Japan, and the
United States before December
2009. All patients had a clinical
diagnosis of CPVT (based on
exercise-induced bidirectional or
polymorphic VT in the absence
of structural cardiac disease) and
a putative pathogenic mutation
in the gene encoding RyR2 or
cardiac calsequestrin. Determi-
nation of flecainide starting dose
and dosing increases were made
by the treating physician as part
of specialized clinical care. Data collection and analysis were
done retrospectively by chart review and were approved by
the institutional review board at each participating
institution.
Primary and secondary outcome measures. Couplets or
VT during exercise are significantly associated with future
arrhythmic events in CPVT (2). Because all patients were
monitored by repeat exercise testing as part of routine
clinical care, we used the reduction of ventricular arrhyth-
mias during exercise testing as the primary outcome mea-
sure. The effect of flecainide was quantified by comparing
the ventricular arrhythmia score (see later text) of the last
exercise test on conventional therapy with the ventricular
arrhythmia score of the first exercise test after a minimum of
5 days on the stable flecainide dose. Only patients on an
unchanged or lower -blocker dose during flecainide treat-
ent were included in the primary analysis. Depending on
he site, exercise testing was performed using a treadmill
standard or modified Bruce protocols) or bicycle ergometer.
Secondary outcome measures were the incidence of ar-
hythmic events (defined as syncope, aborted cardiac arrest,
ppropriate ICD shocks, and sudden cardiac death), assess-
ent of well-being and side effects of flecainide, and
onitoring of proarrhythmic effects of flecainide, in partic-
lar QRS duration during exercise and increase in the
entricular arrhythmia burden (25,26).
efinitions of ventricular arrhythmia. Exercise testing
as analyzed and scored using the following pre-defined
arameters (modified from Rosso et al. [27]): 1) ventricular
rrhythmia score, defined by the worst ventricular arrhyth-
ia (1, no or isolated VPBs; 2, bigeminal VPBs and/or
requent VPBs [10 per min]; 3, couplet; and 4, nonsus-
ained ventricular tachycardia [NSVT], 3 successive
PBs); 2) the presence of either of the parameters of the
entricular arrhythmia score or the presence of bidirectional
T (3 successive VPBs with a beat-to-beat alternating
ight and left QRS axis); 3) sinus rate at the onset of
entricular arrhythmias, most often an isolated VPB; 4)
Abbreviations
and Acronyms
CPVT  catecholaminergic
polymorphic ventricular
tachycardia
ICD  implantable
cardioverter-defibrillator
NSVT  nonsustained
ventricular tachycardia
RyR2  cardiac ryanodine
receptor Ca2 release
channel
VPB  ventricular
premature beat
VT  ventricular
tachycardiaaximum number of VPBs during a 10-s period; and 5)
Baseline Characteristics and Flecainide Therapy ParametersTable 1 Baseline Characteristics and Flecainide Therapy Parameters
Patient
# Sex Mutation*
Age at
First
Symptom,
yrs
Proband or
Relative
Presenting
Symptom
Age at
Diagnosis,
yrs
Aborted
Cardiac
Arrest ICD
Age at
Baseline,
yrs
Drug Therapy at
Baseline,
mg (mg/kg
body weight)
Indication for Starting
Flecainide Treatment
Daily Starting/Stable
Flecainide Dose,
mg (mg/kg
body weight)†
Follow-Up,
months
Response to
Flecainide
Treatment
Side
Effects of
Flecainide
1‡ F A4091T 5 Proband Seizure 6 Yes Yes 13 Nadolol 160 (2.4),
verapamil
180 (2.7)§
NSVT (on Holter
recordings)
300 (4.5) 25 Complete None
2 F R2401H 6 Proband Syncope 6 No No 7 Nadolol 15 (0.9) NSVT (on Holter
recordings)
96 (5.6)/120 (7.1) 22 None None
3‡ M CASQ2: 532
1GA
NA Relative None 3 No Yes 12 Metoprolol
125 (2.3),
verapamil
120 (2.2)§
NSVT (on ICD
recordings) 
frequent ICD shocks
100 (1.9)/150 (2.8) 28 Complete None
4‡ F E4076K 28 Relative Syncope 31 No No 37 Metoprolol
100 (1.6)
Couplets  side effects 100 (1.6)/150 (2.4) 23 Partial None
5 F S4124G NA Relative None 31 No No 36 Bisoprolol
5 (0.08),
verapamil
240 (3.7)§
NSVT  side effects 100 (1.5)/150 (2.3) 28 Partial None
6 F S4124G 45 Proband Syncope 50 No No 68 Bisoprolol
2.5 (0.04)
NSVT  side effects 75 (1.2)/150 (2.4) 13 Partial Sinus arrest
and dizziness
7 F S4124G 26 Relative Aborted cardiac
arrest
26 Yes No 41 None NSVT 150 (2.2) 22 Partial Dizziness
8‡ M S4124G 8 Relative Syncope 8 No No 10 Metoprolol
50 (1.9)
Couplets 50 (1.9)/100 (3.7) 22 Partial None
9‡ M E4187Q NA Proband None (detected by
cardiological
examination
after SCD of
his son)
47 No No 53 Metoprolol
200 (2.4)
NSVT  side effects 150 (1.7) 20 Partial None
10‡ M E4187Q NA Relative None 19 No Yes 25 Metoprolol
200 (2.7)
NSVT 150 (2.0) 20 None None
11‡ F E4187Q NA Relative None 14 No Yes 20 Metoprolol
150 (2.6)
NSVT 100 (1.8) 20 Complete None
12‡ M E4187Q NA Relative None 11 No Yes 17 Metoprolol
100 (1.6)
NSVT 100 (1.6)/300 (4.8) 20 Partial None
13 F E1724K 13 Relative Syncope 13 No No 25 Metoprolol
25 (0.4)
Couplets 100 (1.3)¶# NA# NA# Fatigue, dizziness,
chest pain
14 F E1724K 9 Proband Syncope 15 No No 50 Sotalol 160 (2.1) Bigeminy/frequent VPBs
 side effects
100 (1.3) 20 None None
15‡ M R420W NA Relative None 38 No No 49 Metoprolol
100 (1.3)
Couplets 150 (1.9)/300 (3.9) 19 Complete None
16‡ M R420W NA Relative None 12 No No 16 Metoprolol
100 (1.7)
NSVT 100 (1.7) 19 Complete None
17 F Y4962C NA Relative None 41 No No 45 Atenolol 25 (0.4) NSVT 150 (2.5) 12 Complete None
18‡ F M2605V,
A4510T,
14757-
6_7CTTA
NA Proband None (detected
by exercise
testing at
pre-participation
screening)
40 No No 40 Metoprolol
100 (1.4)
Couplets 200 (2.9) 18 Partial None
Continued on next page
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ContinuedTable 1 Continued
Patient
# Sex Mutation*
Age at
First
Symptom,
yrs
Proband or
Relative
Presenting
Symptom
Age at
Diagnosis,
yrs
Aborted
Cardiac
Arrest ICD
Age at
Baseline,
yrs
Drug Therapy at
Baseline,
mg (mg/kg
body weight)
Indication for Starting
Flecainide Treatment
Daily Starting/Stable
Flecainide Dose,
mg (mg/kg
body weight)†
Follow-Up,
months
Response to
Flecainide
Treatment
Side Effects
of Flecainide
19 F R420W 33 Proband Syncope 33 No Yes 36 Bisoprolol 5 (0.08) Bigeminy/frequent VPBs 100 (1.5) 17 Complete None
20 M R420W NA Relative None 11 No No 12 Atenolol 25 (0.7) Couplets 100 (2.6) 23 Complete None
21‡ F G3946S 14 Proband Syncope 15 No No 34 Nadolol 160 (2.7) Couplets 200 (3.3) 18 Complete None
22 F R420Q 14 Proband Syncope 15 No Yes 20 Bisoprolol
1.25 (0.03)
Couplets 200 (4.0) 17 None None
23‡ F R2474G 1 Proband Convulsion without
fever
11 No Yes 18 Atenolol
100 (2.1),
verapamil
120 (2.6)
NSVT 150 (3.2) 20 Complete None
24 F R420W NA Relative None 20 Yes No 24 Metoprolol
25 (0.4)#
Bigeminy/frequent VPBs
 side effects
100 (1.8) 17 Complete None
25 F E1724K 10 Proband Syncope 31 No No 39 Carvedilol
2.5 (0.05)
NSVT 100 (2.2) 14 Partial None
26‡ F F2215L 5 Proband Cardiac arrest 10 Yes No 24 Propranolol
140 (2.8)
NSVT (on Holter
recordings) 
syncope 
palpitations
100 (2.0) 13 None None
27 F R4157H 56 Relative Palpitations 57 No Yes 57 Bisoprolol
5 (0.08)**
NSVT 150 (2.3) 31 NA** None
28 F M3978I 14 Relative Syncope 15 No Yes 25 Nadolol 40 (0.7) Frequent VPBs 
syncope
150 (2.5) 31 Complete Nausea and
dizziness
29 F M3978I 14 Proband Syncope 14 No Yes 26 Bisoprolol
5 (0.06)††
Bigeminy/frequent VPBs 150 (3.1) 32 None None
30 F M3978I 13 Relative Syncope 32 No No 45 None‡‡ Bigeminy/frequent VPBs 150 (2.3) NA§§ Partial Nausea and
dizziness
31 F M3978I 13 Relative Syncope 38 No No 50 Bisoprolol 5 (0.09) VPBs  palpitations 100 (1.8) NA None Nausea and
dizziness
32 M V4771I 4 Proband Syncope with
seizure
18 No No 18 Sotalol 240 (3.2) NSVT 200 (2.7) 29 yrs¶¶ Complete None
33‡ F R2401H 9 Proband Syncope 9 No Yes 17 Nadolol 160 (2.5) Syncope with VF and
arrhythmic storm
(recorded on ICD log)
150 (2.3) 40 Complete None
Total F: 24
(73%)
RyR2:
32 (97%)
Median:
13
(range
1–56)
Probands:
15 (45%)
Symptoms:
21 (64%)
Median:
18
(range
3–57)
Yes:
4
(12%)
Yes:
12
(36%)
Median:
25
(range
7–68)
-blocker:
31 (94%);
Ca2 channel
blocker:
4 (12%)
Severe ventricular
arrhythmia: 26 (79%);
symptoms: 5 (15%)
Median: 100 (range
50–300)/150
(range 100–300)
Median:
20
(range
12–40)
Complete:
14/31
(45%);
partial:
10/31
(32%)
Yes: 6 (18%)
*RYR2mutations unless otherwise indicated. †Stable dose was identical to starting dose when only 1 dose is displayed. ‡Patients who were treated with a first-line -blocker at an optimal dose (n 15). §Verapamil was discontinued when flecainide was started. This patient
discontinued -blocker therapy during 3 consecutive pregnancies, and thereafter agreed with her treating cardiologist to permanently discontinue -blocker therapy and avoid exercise. ¶Flecainide was discontinued within a few days and before exercise testing on flecainide
could be performed. #Metoprolol was discontinued and flecainide was started in this patient because of intolerable side effects. **This patient was not included in the primary analysis because the bisoprolol dose was also increased. ††This patient discontinued -blocker
therapy on her own initiative after flecainide treatment was started and before an exercise test on combined therapy could be performed. The ventricular arrhythmia score on flecainide monotherapy did not change compared with that on the baseline exercise test while
taking a -blocker. ‡‡This patient discontinued -blocker therapy because of side effects. §§This patient discontinued flecainide and restarted -blocker therapy on her own initiative.  This patient discontinued flecainide because of side effects after exercise testing while
taking a -blocker and flecainide was performed. ¶¶This patient was excluded from the follow-up calculation.
ICD  implantable cardioverter defibrillator; NA  not applicable; NSVT  nonsustained ventricular tachycardia; SCD  sudden cardiac death; VF  ventricular fibrillation; VPB  ventricular premature beat.
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Flecainide Therapy in CPVT May 31, 2011:2244–54ratio of VPBs to sinus beats during the 10-s period with the
maximum number of VPBs.
Reaching a ventricular arrhythmia score of 1 was consid-
ered complete suppression of ventricular arrhythmias. Other
ventricular arrhythmia score improvements were considered
partial suppression.
Statistical analysis. Continuous data are presented as
mean  SD or median (range), and categorical variables as
umber (percentage). Related samples were compared using
he paired Wilcoxon signed-rank test for continuous and
rdinal variables and the McNemar test for dichotomous
ariables. Independent continuous variables were compared
y means of the Mann-Whitney U test. A 2-tailed p value
0.05 was considered statistically significant. Statistical
analysis was performed with SPSS software package, version
15.0 (SPSS, Inc., Chicago, Illinois).
Results
Patient characteristics. A total of 33 genotype-positive
CPVT patients from 21 families were started on flecainide
at 8 tertiary care centers (Table 1). All patients had
persistent physical or emotional stress-induced ventricular
arrhythmias documented by exercise testing, Holter record-
ings, or ICD interrogation and/or persistent symptoms of
palpitations, syncope, aborted cardiac arrest, or appropriate
ICD shocks, while taking -blockers with or without
Ca2-channel blockers. Twenty-four of the patients (73%)
ere female. The median age at the start of flecainide
herapy was 25 years (range 7 to 68 years). Thirty-one
atients (94%) were treated with -blockers, and 4 (12%) of
hem also received Ca2-channel blockers (Table 1).
In 1 patient (Patient #13), flecainide was stopped because
f side effects before exercise testing could be repeated; in
nother patient (Patient #27) the -blocker dose was
ncreased during flecainide treatment; and 2 patients (Pa-
ients #7 and #30) did not receive -blocker therapy when
flecainide was started (Table 1). In the remaining 29
patients, exercise tests on combination therapy of flecainide
with conventional drugs at unchanged or lower doses were
available for analysis. In 17 patients (59%), baseline exercise
testing was performed 48 h before flecainide initiation.
Flecainide therapy reduces exercise-induced ventricular
arrhythmias. Flecainide treatment improved the ventric-
ular arrhythmia score in 22 patients (76%) (p  0.001)
(Fig. 1A). Fourteen patients (48%) had complete suppres-
sion of ventricular arrhythmias (including 7 patients without
any VPBs), and 8 (28%) had partial suppression. None of
the patients experienced significant (i.e., couplet or VT)
worsening of the exercise-induced ventricular arrhythmia
score.
Flecainide treatment also significantly improved all other
predefined parameters of exercise-induced ventricular ar-
rhythmia (Table 2). For example, patients receiving flecain-
ide therapy achieved significantly higher heart rates before
ventricular arrhythmias occurred. Independently, flecainide acaused a significant reduction in maximum sinus rate
during exercise, even though a higher mean workload was
achieved. As expected (28), flecainide prolonged the PR
interval (149 21 ms vs. 160 24 ms; p 0.003), and the
RS duration (83  9 ms vs. 89  11 ms; p  0.005), but
id not change the QTc interval (399 26 ms vs. 405 19
s; p  0.171) at rest. These parameters remained within
he normal range at rest and during peak exercise in all
atients, except for a slightly prolonged resting PR interval
220 ms) in 1 patient (Patient #20).
We next assessed the reproducibility of exercise testing as
measure of the ventricular arrhythmia burden in CPVT.
lthough not available for all patients, a subset of patients
nderwent repeated exercise testing either at the same dose
f conventional therapy (n  14) or at the same flecainide
ose (n  16). In both cases, the ventricular arrhythmia
core of the second exercise test was not statistically different
rom that on the first exercise test (Fig. 2). Similarly, all
ther predefined parameters of exercise-induced ventricular
rrhythmia also did not change significantly (e.g., the
aximum number of VPBs during a 10-s period was 5  5
n the first exercise test at the stable flecainide dose and 6
on the second exercise test at the same flecainide dose
p  0.556]), suggesting that ventricular arrhythmia scores
btained from exercise testing are reproducible measures of
rug efficacy in CPVT and that tachyphylaxis was not
resent.
We found that 14 of the 29 patients included in the
rimary analysis received drug therapy that could be con-
idered suboptimal (i.e., an unusual -blocker for CPVT
bisoprolol, carvedilol, or sotalol]) or a relatively low
-blocker dose (atenolol, metoprolol, or nadolol 1 mg/kg
ody weight daily) (2). These patients had either side effects
n other -blockers and/or a higher -blocker dose, or
adolol was not available in their country. To assess whether
ecainide was also effective in CPVT patients on optimal
onventional therapy, we next analyzed the 15 patients who
ere treated with a first-line -blocker at an optimal dose
(Table 1). Flecainide significantly improved the ventricular
arrhythmia score (p  0.003) (Fig. 1B), and all other
pre-defined arrhythmia parameters in this subgroup to a
similar extent as in the primary analysis.
The ventricular arrhythmia score in the 2 patients (Patients
#7 and #30) who did not receive -blocker therapy when fle-
ainide was started improved from NSVT to couplet and from
SVT to bigeminal VPBs and frequent VPBs, respectively.
lecainide dose in CPVT. To estimate the optimal dosing
f flecainide in CPVT, we analyzed the relationship be-
ween starting dose and VT suppression during the first
xercise test on flecainide. Patients without suppression of
xercise-induced ventricular arrhythmias on the starting
ecainide dose received a significantly lower dose (113 39
g, n  13; p  0.038) compared with patients with either
artial (142  38 mg, n  6) or complete ventricular
rrhythmia suppression (150  60 mg, n  12). Eight
2249JACC Vol. 57, No. 22, 2011 van der Werf et al.
May 31, 2011:2244–54 Flecainide Therapy in CPVTpatients (24%) received an increased flecainide dose after the
initial exercise test (Table 1). The dose increased from an
average daily dose of 96  28 mg to 178  78 mg (range
100 to 300 mg), which resulted in a significant improvement
in the ventricular arrhythmia score (Fig. 3).
Clinical follow-up. Three patients (Patients #13, #30, and
#31) discontinued flecainide with 6 months of follow-up
due to side effects. One patient (Patient #6) required a
Figure 1 Ventricular Arrhythmia Score on Standard Therapy and
Ventricular arrhythmia score per patient on the baseline exercise test on standard
cohort (n  29) (A) and in the patients who were treated with a first-line -blocker
mia category and change in ventricular arrhythmia category are shown. The line th
median time interval between the 2 tests is shown. All exercise tests were perform
ular tachycardia; VPB  ventricular premature beats.pacemaker because flecainide exacerbated pre-existing sinusnode dysfunction. Flecainide was resumed after pacemaker
implantation, and this patient was included in the study. In
2 patients (Patients #7 and #28), the stable flecainide dose
was decreased because of dizziness. All other patients
tolerated flecainide well without severe side effects. The
-blocker dose was decreased in 5 patients (Patients #4, #5,
#6, #9, and #12) who had a partial suppression of ventricular
arrhythmias on flecainide and experienced side effects of
Flecainide
py and on the first exercise test on the final (stable) flecainide dose in the entire
optimal dose (n  15) (B). The number of patients in each ventricular arrhyth-
s indicates the number of patients, and a dotted line represents 1 patient. The
patients receiving an unchanged -blocker dose. NSVT  nonsustained ventric-on
thera
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Flecainide Therapy in CPVT May 31, 2011:2244–54was started. One patient (Patient #29) refused to take
-blockers during follow-up, with no worsening of exercise-
induced ventricular arrhythmias on flecainide monotherapy.
Thus, 30 of 33 patients (91%) continued to receive
flecainide and were included in the further analysis of the
incidence of arrhythmic events. During a median follow-up
of 20 months (range 12 to 40 months, excluding Patient
#32), VT recurred in only 1 patient (Patient #1) who
experienced several appropriate ICD shocks for polymor-
phic VT after 8 months of flecainide treatment. Her serum
flecainide level was low (0.34 g/ml) at the time of the event
compared with levels obtained previously (0.75 to 0.82
g/ml), suggesting noncompliance. She was hospitalized for
48 h, nadolol and flecainide were resumed at their previous
doses, and no further ventricular arrhythmias occurred
during a further follow-up of 17 months. The other 29
patients remained free of arrhythmic events during follow-
up. The longest follow-up of 29 years was achieved in
Patient #32, who presented with exercise-induced VT in
1981. After unsuccessful trials of multiple antiarrhythmic
drugs (including mexilitine, amiodarone, propranolol, sota-
lol, and Ca2-channel blockers), flecainide (200 mg/day)
as added to sotalol (160 mg/day), which resulted in
omplete suppression of ventricular arrhythmia during ex-
rcise testing. In 2008, an exercise test 48 h after stopping
ecainide and sotalol showed NSVT. After restarting the
ombined therapy, a subsequent exercise test only showed
solated VPBs, but no VT. Subsequent genotyping revealed
mutation in the gene encoding RyR2. In Patient #33,
ecainide 150 mg/day was started in 2007 because of 2
pisodes of syncope with ventricular fibrillation on the ICD
nterrogation despite nadolol 240 mg/day. Exercise testing
Exercise Test Results of the Baseline Exercise Test on Standard Ton the First Exercise Tes on the Fi al (Stable) Flecai ide DoseTable 2 Results of the Bas lin Exercise Test onon the First Exercise Test on the Final (Stable) Flecain
Stan
Time after start flecainide, days
Sinus rate at baseline, beats/min
Sinus rate at maximal exercise, beats/min 1
Maximum workload attained, METs
Sinus rate at onset of ventricular arrhythmias, beats/min 1
Maximum no. of VPBs during a 10-s period†
Ratio of VPBs to sinus beats during the 10-s period with
the maximum no. of VPBs†
Isolated VPB
Bigeminal VPBs
Frequent VPBs (10/min)
Couplet
Nonsustained ventricular tachycardia
Longest ventricular salvo, VPBs†
Bidirectional NSVT
Data are mean  SD, median (range), or n (%). *Only the 22 patients who still had ventricular arrh
vailable for 28 patients (not available for Patient #32).
MET  metabolic equivalent; NSVT  nonsustained ventricular tachycardia; VPB  ventricularhowed complete suppression of ventricular arrhythmias,nd she has been free of arrhythmic events on flecainide for
0 months.
iscussion
ain findings. Our study demonstrates that flecainide
educes or prevents exercise-induced ventricular arrhyth-
ias in the majority of CPVT patients receiving conven-
ional drug therapy. These findings are important because
everal studies have demonstrated a significant failure rate of
urrent drug therapy (1,3,11–16), including potentially fatal
rrhythmic events in 11% of CPVT patients over an 8-year
eriod (2). Based on our clinical experience reported here,
ecainide in addition to -blocker therapy should be con-
sidered for CPVT patients who otherwise have few alter-
native therapeutic options. The optimal dose appears to be
between 150 and 200 mg/day (range 100 to 300 mg/day).
Daily doses 100 mg were associated with a lack of
therapeutic response.
Rationale for use of flecainide. CPVT is caused by mu-
tations in the genes encoding RyR2 and cardiac calseques-
trin (4,5), 2 proteins that control Ca2 release from the
arcoplasmic reticulum. As a result of the mutations, Ca2
is released prematurely and excessively into the cytosol
under conditions of catecholaminergic stimulation, gener-
ating repetitive spontaneous Ca2 waves (9,29). The in-
rease in intracellular Ca2 in turn activates the electrogenic
a/Ca2 exchanger, which produces a transient inward
current (ITi). ITi generates delayed afterdepolarizations,
which can lead to triggered activity, and the initiation of
ventricular arrhythmias (30). Flecainide directly targets the
molecular defect in CPVT by inhibiting RyR2 channels and
y andnd rd Therapy and
ose
herapy
ne
9)
First Exercise Test on
Stable Flecainide Dose
(n  29) p Value
21 (5–363) —
10 59 9 0.061
23 133 18 0.002
3 12 4 0.042
19 118 19 0.046*
5 5 5 0.001
0.8 0.4 0.4 0.001
0) 22 (76) 0.016
) 13 (45) 0.001
) 14 (48) 0.001
) 2 (7) 0.001
) 1 (3) 0.002
9) 4 —
) — —
s on the first exercise test at the stable flecainide dose were included in this analysis. †Data were
ure beat.herapSta
ide D
dard T
Baseli
(n  2
—
57
45
11
13
12
1.2
29 (10
28 (97
27 (93
20 (69
11 (38
5 (3–
4 (36
ythmiapreventing arrhythmogenic Ca2 waves (23,24). Flecain-
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May 31, 2011:2244–54 Flecainide Therapy in CPVTide’s Na-channel blockade further reduces the rate of
triggered beats (23,24). This dual action could explain why
flecainide is so effective in severe CPVT and provides a
Figure 2 Reproducibility of Ventricular Arrhythmia Score on Ex
Ventricular arrhythmia score per patient on the baseline exercise test and on the
ond exercise tests at the final (stable) flecainide dose (B). The number of patients
are shown. The line thickness indicates the number of patients, and a dotted line
standard therapy exercise tests were performed on patients receiving the same 
receiving flecainide were at the same stable flecainide dose in combination with a
and second exercise tests on flecainide were not significantly different (140  19
of 4 and 3 on the second exercise test did reach a significantly higher maximum sinu
tively). Abbreviations as in Figure 1.rationale for combination therapy with -blockers.RyR2-mediated sarcoplasmic reticulum Ca2 release im-
portantly regulates the beating rate of sinoatrial nodal cells
(31), especially in response to catecholamines (32), and
Testing
s exercise test at the same standard therapy dose (A) and on the first and sec-
ch ventricular arrhythmia category and change of ventricular arrhythmia category
sents 1 patient. The median time interval between the 2 tests is shown. The
r dose with or without Ca2-channel blocker. All exercise tests on patients
anged or lower -blocker dose. The sinus rates at maximal exercise on the first
4  20; p  0.245). However, the 2 patients with a ventricular arrhythmia score
compared with the first exercise test (increase of 32 and 19 beats/min, respec-ercise
previou
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Flecainide Therapy in CPVT May 31, 2011:2244–54reticulum Ca2 release in myocytes (24). This mechanism
ay explain why maximum hearts rates were significantly
ower in flecainide-treated patients even though workloads
ere higher compared with baseline exercise testing (Table 2).
he reduction in sinus rate during exercise may further
ontribute to flecainide’s efficacy in CPVT.
linical implications. Given the high fatality rate of
ntreated CPVT patients (1,2), adequate treatment is man-
atory and potentially life-saving. -blockers are considered
first-line therapy. In the largest published series of patients
with CPVT, the risk of cardiac arrest (defined as aborted
cardiac arrest, appropriate ICD shocks, and sudden cardiac
death), despite -blocker therapy during a mean follow-up
eriod of 8 years, was 11% (2). Others have reported very
iverse fatal or near-fatal event rates despite -blocker
herapy (1,3,11–16), although the highest event rates may
e explained by the predominance of (symptomatic) pro-
ands and underdosing of -blockers. An ICD was recom-
ended for CPVT patients who were survivors of cardiac
rrest, or when syncope or sustained VT persisted despite
aximum tolerable -blockade (33). Yet, ICDs have a
otentially harmful effect in CPVT patients (17,18). More-
ver, many CPVT patients are children, in whom ICD
mplantation can lead to significant complications (34).
hus, to avoid ICD implantation and prevent ICD shocks
n patients with ICDs, controlling ventricular arrhythmias is
f great clinical importance. Alternative therapies are
Figure 3 Dose Dependence of Flecainide in 8 CPVT Patients W
The number of patients in each ventricular arrhythmia category and change in vent
 28 mg; range 50 to 150 mg) and on the first exercise test at the final (stable)
indicates the number of patients, and a dotted line represents 1 patient. The med
performed with the patients receiving an unchanged -blocker dose. Abbreviationseeded for CPVT patients.Left cardiac sympathetic denervation is an effective alter-
ative when symptoms persist despite -blockade, but
requires surgery, is not universally available, and has only
been tested in small cohorts (19–22). The use of Ca2-
channel blockers in addition to -blockade has been re-
ported to decrease ventricular ectopy in CPVT patients with
continuous symptoms and/or exercise-induced ventricular
arrhythmias (12,27,35), but is not effective in all patients
(27,35,36). From the original 6 patients treated with vera-
pamil and -blockers after failure of -blockers alone,
eported by Rosso et al. (27) in 2007, 3 had clinically
ignificant ventricular arrhythmias during 37 6 months of
ollow-up (36). Other pharmacological agents, including
a-channel blockers, amiodarone, and magnesium, lack of
fficacy in CPVT patients (1,12).
In this analysis of all consecutive patients started on
ecainide at 8 international centers, adding flecainide to
tandard therapy was effective in further reducing exercise-
nduced VT and preventing arrhythmic events CPVT pa-
ients. To suppress CPVT, adequate dosing of flecainide
eems critical. An increased dose may be effective when the
nitial dose of flecainide fails to suppress VT. Based on these
esults, flecainide could be added to -blocker therapy when
ymptoms or either spontaneous or exercise-induced ven-
ricular arrhythmias persist despite -blocker.
In our young patient population with no structural heart
disease, the proarrhythmic effect of flecainide as docu-
ad an Increase in Flecainide Dose
arrhythmia category on the last exercise test at the flecainide starting dose (96
ide dose (178  78 mg; range 100 to 300 mg) is shown. The line thickness
e interval from the start of flecainide therapy is shown. All exercise tests were
Figure 1.ho H
ricular
flecain
ian tim
as inmented in patients with ischemia and impaired left ventric-
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May 31, 2011:2244–54 Flecainide Therapy in CPVTular function (37) may not be applicable. Consistent with
this hypothesis, flecainide did not cause arrhythmic events
during a median follow-up of 20 months, which is longer
than the mean follow-up of 10 months in the CAST
(Cardiac Arrhythmia Suppression Trial). The only arrhyth-
mic event was associated with low flecainide serum levels,
suggesting that the event was due to the underdosing and
not toxicity.
Study limitations. This study reports on our experience of
using flecainide in a clinical setting. The number of patients
is relatively small because CPVT is a rare condition and only
patients without other treatment alternatives were started
on flecainide. However, it is the largest evaluation of a new
therapeutic strategy in CPVT patients refractory to current
drug therapy, with a median of 20 months follow-up. One
patient has received flecainide for 29 years with continuous
VT suppression on unchanged doses, and another severely
symptomatic patient has been free of arrhythmic events on
flecainide for 40 months. Nevertheless, long-term follow-up
in more patients would further support the clinical utility of
flecainide in CPVT.
Another potential limitation is that we only quantified
the effect of flecainide on exercise-induced ventricular ar-
rhythmias, which may not accurately predict fatal arrhyth-
mic events. However, exercise testing is clinically used to
guide therapy in CPVT. In a previous study including 70
CPVT patients, exercise-induced couplets or more succes-
sive VPBs were significantly associated with future arrhyth-
mic events (sensitivity, 0.62; specificity, 0.67) (2).
Furthermore, we cannot exclude potential bias introduced
by the variability of exercise test results on unchanged
treatment, as illustrated in Figure 2. Finally, in 14 patients,
conventional therapy may be considered suboptimal because
they received an unusual -blocker for CPVT or a low
-blocker dose for reasons previously outlined. However,
flecainide was equally effective in the subgroup of CPVT
patients who were treated with a first-choice -blocker at an
adequate dose (Fig. 1B).
Conclusions
Our results suggest that flecainide is a safe and effective
therapy to reduce ventricular arrhythmias in the majority of
CPVT patients who have exercise-induced ventricular ar-
rhythmias despite conventional therapy.
Reprint requests and correspondence: Dr. Arthur A. M. Wilde,
Academic Medical Center, University of Amsterdam, Department
of Cardiology, Heart Failure Research Center, Meibergdreef 9,
1105 AZ Amsterdam, the Netherlands. E-mail: a.a.wilde@
amc.uva.nl. OR Dr. Björn C. Knollmann, Oates Institute for
Experimental Therapeutics, Vanderbilt University School of Med-
icine, Division of Clinical Pharmacology, Medical Research Build-
ing IV, Room 1265, 2215B Garland Avenue, Nashville, Tennessee
37232-0575. E-mail: bjorn.knollmann@vanderbilt.edu.REFERENCES
1. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P.
Catecholaminergic polymorphic ventricular tachycardia in children. A
7-year follow-up of 21 patients. Circulation 1995;91:1512–9.
2. Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors
of arrhythmic events in catecholaminergic polymorphic ventricular
tachycardia. Circulation 2009;119:2426–34.
3. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular
characterization of patients with catecholaminergic polymorphic ven-
tricular tachycardia. Circulation 2002;106:69–74.
4. Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac
ryanodine receptor gene (hRyR2) underlie catecholaminergic polymor-
phic ventricular tachycardia. Circulation 2001;103:196–200.
5. Lahat H, Pras E, Olender T, et al. A missense mutation in a highly
conserved region of CASQ2 is associated with autosomal recessive
catecholamine-induced polymorphic ventricular tachycardia in Bed-
ouin families from Israel. Am J Hum Genet 2001;69:1378–84.
6. Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, et al. The RYR2-
encoded ryanodine receptor/calcium release channel in patients diag-
nosed previously with either catecholaminergic polymorphic ventricu-
lar tachycardia or genotype negative, exercise-induced long QT
syndrome: a comprehensive open reading frame mutational analysis.
J Am Coll Cardiol 2009;54:2065–74.
7. Jiang D, Xiao B, Yang D, et al. RyR2 mutations linked to ventricular
tachycardia and sudden death reduce the threshold for store-overload-
induced Ca2 release (SOICR). Proc Natl Acad Sci U S A 2004;
101:13062–7.
8. di Barletta MR, Viatchenko-Karpinski S, Nori A, et al. Clinical
phenotype and functional characterization of CASQ2 mutations
associated with catecholaminergic polymorphic ventricular tachycar-
dia. Circulation 2006;114:1012–9.
9. Knollmann BC, Chopra N, Hlaing T, et al. Casq2 deletion causes
sarcoplasmic reticulum volume increase, premature Ca2 release, and
catecholaminergic polymorphic ventricular tachycardia. J Clin Invest
2006;116:2510–20.
10. Cerrone M, Noujaim SF, Tolkacheva EG, et al. Arrhythmogenic
mechanisms in a mouse model of catecholaminergic polymorphic
ventricular tachycardia. Circ Res 2007;101:1039–48.
11. Bauce B, Rampazzo A, Basso C, et al. Screening for ryanodine
receptor type 2 mutations in families with effort-induced polymorphic
ventricular arrhythmias and sudden death: early diagnosis of asymp-
tomatic carriers. J Am Coll Cardiol 2002;40:341–9.
12. Sumitomo N, Harada K, Nagashima M, et al. Catecholaminergic
polymorphic ventricular tachycardia: electrocardiographic characteris-
tics and optimal therapeutic strategies to prevent sudden death. Heart
2003;89:66–70.
13. Postma AV, Denjoy I, Kamblock J, et al. Catecholaminergic polymor-
phic ventricular tachycardia: RYR2 mutations, bradycardia, and follow
up of the patients. J Med Genet 2005;42:863–70.
14. Lahat H, Eldar M, Levy-Nissenbaum E, et al. Autosomal recessive
catecholamine- or exercise-induced polymorphic ventricular tachycar-
dia: clinical features and assignment of the disease gene to chromo-
some 1p13-21. Circulation 2001;103:2822–7.
15. Swan H, Piippo K, Viitasalo M, et al. Arrhythmic disorder mapped to
chromosome 1q42-q43 causes malignant polymorphic ventricular
tachycardia in structurally normal hearts. J Am Coll Cardiol 1999;34:
2035–42.
16. Haugaa KH, Leren IS, Berge KE, et al. High prevalence of exercise-
induced arrhythmias in catecholaminergic polymorphic ventricular
tachycardia mutation-positive family members diagnosed by cascade
genetic screening. Europace 2010;12:417–23.
17. Mohamed U, Gollob MH, Gow RM, Krahn AD. Sudden cardiac
death despite an implantable cardioverter-defibrillator in a young
female with catecholaminergic ventricular tachycardia. Heart Rhythm
2006;3:1486–9.
18. Pizzale S, Gollob MH, Gow R, Birnie DH. Sudden death in a young
man with catecholaminergic polymorphic ventricular tachycardia and
paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 2008;19:
1319–21.
19. Wilde AA, Bhuiyan ZA, Crotti L, et al. Left cardiac sympathetic
denervation for catecholaminergic polymorphic ventricular tachycar-
dia. N Engl J Med 2008;358:2024–9.
33
3
3
3
3
3
3
2254 van der Werf et al. JACC Vol. 57, No. 22, 2011
Flecainide Therapy in CPVT May 31, 2011:2244–5420. Odero A, Bozzani A, De Ferrari GM, Schwartz PJ. Left cardiac
sympathetic denervation for the prevention of life-threatening arrhyth-
mias: the surgical supraclavicular approach to cervicothoracic sympa-
thectomy. Heart Rhythm 2010;7:1161–5.
21. Makanjee B, Gollob MH, Klein GJ, Krahn AD. Ten-year follow-up
of cardiac sympathectomy in a young woman with catecholaminergic
polymorphic ventricular tachycardia and an implantable cardioverter
defibrillator. J Cardiovasc Electrophysiol 2009;20:1167–9.
22. Collura CA, Johnson JN, Moir C, Ackerman MJ. Left cardiac
sympathetic denervation for the treatment of long QT syndrome and
catecholaminergic polymorphic ventricular tachycardia using video-
assisted thoracic surgery. Heart Rhythm 2009;6:752–9.
23. Watanabe H, Chopra N, Laver D, et al. Flecainide prevents cat-
echolaminergic polymorphic ventricular tachycardia in mice and hu-
mans. Nat Med 2009;15:380–3.
24. Hilliard FA, Steele DS, Laver D, et al. Flecainide inhibits arrhyth-
mogenic Ca2 waves by open state block of ryanodine receptor Ca2
release channels and reduction of Ca2 spark mass. J Mol Cell
Cardiol 2010;48:293–301.
25. Anastasiou-Nana MI, Anderson JL, Stewart JR, et al. Occurrence of
exercise-induced and spontaneous wide complex tachycardia during
therapy with flecainide for complex ventricular arrhythmias: a probable
proarrhythmic effect. Am Heart J 1987;113:1071–7.
26. Katritsis D, Rowland E, O’Nunain S, Shakespeare CF, Poloniecki J,
Camm AJ. Effect of flecainide on atrial and ventricular refractoriness
and conduction in patients with normal left ventricle. Implications for
possible antiarrhythmic and proarrhythmic mechanisms. Eur Heart J
1995;16:1930–5.
27. Rosso R, Kalman JM, Rogowski O, et al. Calcium channel blockers
and beta-blockers versus beta-blockers alone for preventing exercise-
induced arrhythmias in catecholaminergic polymorphic ventricular
tachycardia. Heart Rhythm 2007;4:1149–54.
28. Roden DM, Woosley RL. Drug therapy. Flecainide. N Engl J Med
1986;315:36–41.29. George CH, Higgs GV, Lai FA. Ryanodine receptor mutations
associated with stress-induced ventricular tachycardia mediate in-creased calcium release in stimulated cardiomyocytes. Circ Res 2003;
93:531–40.
0. Schlotthauer K, Bers DM. Sarcoplasmic reticulum Ca(2) release
causes myocyte depolarization. Underlying mechanism and threshold
for triggered action potentials. Circ Res 2000;87:774–80.
1. Maltsev VA, Lakatta EG. Dynamic interactions of an intracellular
Ca2 clock and membrane ion channel clock underlie robust initia-
tion and regulation of cardiac pacemaker function. Cardiovasc Res
2008;77:274–84.
2. Vinogradova TM, Bogdanov KY, Lakatta EG. beta-Adrenergic stim-
ulation modulates ryanodine receptor Ca(2) release during diastolic
depolarization to accelerate pacemaker activity in rabbit sinoatrial
nodal cells. Circ Res 2002;90:73–9.
3. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006
guidelines for management of patients with ventricular arrhythmias
and the prevention of sudden cardiac death: a report of the American
College of Cardiology/American Heart Association Task Force and
the European Society of Cardiology Committee for Practice Guide-
lines (Writing Committee to Develop Guidelines for Management of
Patients With Ventricular Arrhythmias and the Prevention of Sudden
Cardiac Death). J Am Coll Cardiol 2006;48:e247–346.
4. Sherrid MV, Daubert JP. Risks and challenges of implantable
cardioverter-defibrillators in young adults. Prog Cardiovasc Dis 2008;
51:237–63.
5. Swan H, Laitinen P, Kontula K, Toivonen L. Calcium channel
antagonism reduces exercise-induced ventricular arrhythmias in cat-
echolaminergic polymorphic ventricular tachycardia patients with
RyR2 mutations. J Cardiovasc Electrophysiol 2005;16:162–6.
6. Rosso R, Kalman J, Rogowsky O, et al. Long-term effectiveness of
beta blocker and calcium blocker combination therapy in patients with
CPVT. Heart Rhythm 2010;7:S423.
7. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in
patients receiving encainide, flecainide, or placebo. The Cardiac
Arrhythmia Suppression Trial. N Engl J Med 1991;324:781–8.Key Words: antiarrhythmia agents y catecholaminergic polymorphic
ventricular tachycardia y ventricular arrhythmia.
